Finvest
BSX Medical Devices · Medical devices · Large cap · Health care · Thesis updated June 12, 2026

Strong devices, one big deal risk

01 Running thesis

Growth meets FTC friction

Boston Scientific is still executing well. In Q1 2026, organic sales grew 9.4%. The main driver is FARAPULSE, a pulsed field ablation system used to treat certain abnormal heart rhythms. That product has turned from a launch story into a real sales engine.

The bull case is simple. BSX has a broad medical device base, strong doctor relationships, and a habit of buying promising assets, then selling them through its global sales force. If the Penumbra acquisition closes, BSX would gain a bigger role in thrombectomy, which means devices that remove blood clots.

The bear case has become more serious. BSX and Penumbra received an FTC Second Request, which means the regulator wants more information before deciding on the deal. That can lead to a delay, required divestitures, extra costs, or a block. Since the Penumbra deal is a major part of the next growth story, this is now the biggest near-term swing factor.

There are also early cracks to watch inside the core business. The Q1 2026 filing noted deceleration in WATCHMAN procedures and more competition in Electrophysiology. BSX still has strong momentum, but the story is no longer only about product wins. It is also about whether the biggest deal in company history can close and earn its price.

May 2026▼Q1 2026 confirmed strong 9.4% organic growth, but BSX and Penumbra received an FTC Second Request. That adds real approval risk to the $14.5 billion acquisition.
Feb 2026▲The 2025 10-K showed 19.9% reported sales growth and continued strength from FARAPULSE. BSX also announced the planned Penumbra acquisition, adding a large new growth target with higher integration risk.
Nov 2025▲Q3 2025 sales grew 20.3% reported and 15.3% organic. FARAPULSE, WATCHMAN, and recent acquisitions continued to support the growth thesis.
Aug 2025▲Q2 2025 sales grew 22.8% reported and 17.4% organic. FARAPULSE adoption stayed strong, while Axonics helped Urology growth.
May 2025▲Q1 2025 sales grew 20.9% reported and 18.2% organic. FARAPULSE moved from a launch catalyst to a proven growth driver.
Feb 2025→The initial thesis framed BSX as a diversified medical device company with strong 2024 growth. The main watch items were FARAPULSE adoption and integration of Axonics and Silk Road Medical.
02 Business model

Less invasive tools, sold worldwide

Boston Scientific develops, makes, and sells medical devices for procedures that often replace more invasive surgery. Hospitals and doctors use its tools in heart, blood vessel, digestive, bladder, nerve, pain, and cancer procedures.

The company makes money by selling devices and related systems across two segments: Cardiovascular and MedSurg. Its edge comes from patents, clinical data, trained sales teams, long doctor relationships, and knowing how to get devices cleared by regulators.

Growth comes from two paths. First, BSX improves and launches new products, like FARAPULSE and AGENT. Second, it buys companies in nearby markets, such as Axonics, Silk Road Medical, and now proposed Penumbra. That strategy can work well, but it depends on paying the right price, closing deals, and fitting new products into the sales machine.

Where it can break: regulators can delay approvals, insurers can reduce payment, hospitals can push back on price, rivals can copy or beat products, and acquired businesses can disappoint. For BSX, the current test is whether strong organic growth can offset the risk around the Penumbra deal.

03 Product portfolio

Devices that drive the story

Growth engine

FARAPULSE

FARAPULSE is a pulsed field ablation system for Electrophysiology. It led recent growth, but the Q1 2026 filing also flagged more competition in this area.

Cash cow

WATCHMAN

WATCHMAN closes the left atrial appendage in certain heart patients to reduce stroke risk. It has been a major growth product, though procedure growth has started to slow.

Steady

Interventional Cardiology

This group includes coronary stents, imaging catheters, and AGENT drug-coated balloons. It gives BSX a broad base in heart procedures beyond ablation and WATCHMAN.

Growth engine

Urology and Axonics

Urology includes kidney stone, prostate, and incontinence products. The Axonics acquisition added sacral neuromodulation systems and helped drive 2025 segment growth.

Steady

Endoscopy

Endoscopy sells tools for digestive system procedures, including EXALT single-use scopes, Resolution 360 clips, and AXIOS stents. It is a steady part of MedSurg.

Option

Peripheral Interventions and Silk Road

This group treats peripheral artery and vein disease, liver cancer, and stroke risk. Silk Road Medical added a stroke prevention platform that BSX still needs to scale.

Option

Penumbra thrombectomy

Penumbra would add clot removal products such as Lightning Bolt and Lightning Flash CAVT systems. The deal is pending and now faces an FTC Second Request.

04 Business segments

Cardiovascular leads the mix

Cardiovascular66%growing fast
MedSurg34%growing fast

Segment mix is based on full-year 2025 net sales. Cardiovascular was 66% of sales, so BSX is most exposed to heart and vascular procedure trends.

05 Risk factors

What could break the thesis

FTC blocks or delays Penumbra

High impact · Medium odds

The Penumbra deal is valued at about $14.5 billion and is a major part of the growth plan. The FTC Second Request raises the chance that closing takes longer, needs remedies, or fails. A blocked deal would leave a gap in the thrombectomy expansion story.

We watchFTC review updates, deal close timing, and any required divestitures or remedies.

FARAPULSE loses speed

High impact · Medium odds

FARAPULSE has been a major driver of recent growth. If competitors win share or doctors slow adoption, the fastest part of the story weakens. The Q1 2026 filing already noted increased competition in Electrophysiology.

We watchElectrophysiology growth rates, management comments on share, and rival pulsed field ablation launches.

WATCHMAN procedures slow further

Medium impact · Medium odds

WATCHMAN has been one of BSX's important heart franchises. The Q1 2026 filing noted procedure deceleration. If this continues, it could offset strength from FARAPULSE and other cardiology products.

We watchWATCHMAN sales growth, LAAC procedure volumes, and comments on patient flow.

Acquisitions fail to earn their price

High impact · Medium odds

BSX uses acquisitions to enter faster-growing adjacent markets. Axonics, Silk Road Medical, and the planned Penumbra deal all need to add growth after purchase. If sales synergies are weak or costs rise, returns could fall short.

We watchOrganic growth from acquired businesses, synergy targets, integration costs, and margin progress.

Pricing and reimbursement pressure

Medium impact · High odds

Hospitals, insurers, and government health systems push medical device prices lower. If reimbursement changes make procedures less profitable for doctors or hospitals, demand can slow. This risk is common in medical devices, but it matters more when growth expectations are high.

We watchMedicare and private payer coverage changes, hospital purchasing pressure, and tender pricing in international markets.
06 Quick answers

In one breath

What does Boston Scientific actually sell?

It sells medical devices used in less invasive procedures. Its biggest areas include heart devices, blood vessel tools, digestive procedure tools, urology devices, and neuromodulation systems for pain and movement disorders.

Why is FARAPULSE important for BSX?

FARAPULSE is a pulsed field ablation system used in Electrophysiology. It has led recent growth and is one of the main reasons the company has been growing faster than many medical device peers.

Why does the Penumbra deal matter?

Penumbra would give BSX a larger position in thrombectomy, which means removing blood clots. The deal is large at about $14.5 billion, and the FTC Second Request makes approval timing and final terms uncertain.